Gleason C - Search Results

1

Improving induction therapy in multiple myeloma.

Nooka A, Gleason C, Lonial S. Nooka A, et al. Among authors: gleason c. Curr Hematol Malig Rep. 2010 Jul;5(3):119-28. doi: 10.1007/s11899-010-0057-7. Curr Hematol Malig Rep. 2010. PMID: 20449692 Review.

2

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

Nooka AK, Kaufman JL, Muppidi S, Langston A, Heffner LT, Gleason C, Casbourne D, Saxe D, Boise LH, Lonial S. Nooka AK, et al. Among authors: gleason c. Leukemia. 2014 Mar;28(3):690-3. doi: 10.1038/leu.2013.335. Epub 2013 Nov 13. Leukemia. 2014. PMID: 24220275

3

Supportive therapies in multiple myeloma.

Gleason C, Nooka A, Lonial S. Gleason C, et al. J Natl Compr Canc Netw. 2009 Oct;7(9):971-9. doi: 10.6004/jnccn.2009.0064. J Natl Compr Canc Netw. 2009. PMID: 19878640 Review.

4

Treatment of relapsed and refractory myeloma.

Kaufman J, Gleason C, Lonial S. Kaufman J, et al. Among authors: gleason c. Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5. Curr Hematol Malig Rep. 2009. PMID: 20425421 Review.

5

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S. Kaufman JL, et al. Among authors: gleason c. Cancer. 2010 Jul 1;116(13):3143-51. doi: 10.1002/cncr.25143. Cancer. 2010. PMID: 20564642 Free article.

6

Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials.

Nooka AK, Kaufman JL, Behera M, Langston A, Waller EK, Flowers CR, Gleason C, Boise LH, Lonial S. Nooka AK, et al. Among authors: gleason c. Cancer. 2013 Dec 1;119(23):4119-28. doi: 10.1002/cncr.28325. Epub 2013 Sep 4. Cancer. 2013. PMID: 24005889 Free article. Clinical Trial.

7

Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab.

Nooka AK, Gleason C, Sargeant MO, Walker M, Watson M, Panjic EH, Lonial S. Nooka AK, et al. Among authors: gleason c. J Oncol Pract. 2018 Jul;14(7):414-422. doi: 10.1200/JOP.18.00143. J Oncol Pract. 2018. PMID: 29996069 Review.

8

Daratumumab and its use in the treatment of relapsed and/or refractory multiple myeloma.

Chehab S, Panjic EH, Gleason C, Lonial S, Nooka AK. Chehab S, et al. Among authors: gleason c. Future Oncol. 2018 Dec;14(30):3111-3121. doi: 10.2217/fon-2018-0275. Epub 2018 Aug 23. Future Oncol. 2018. PMID: 30136602 Review.

9

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study.

Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, Nooka AK, Harvey RD, Lonial S. Kaufman JL, et al. Among authors: gleason c. Blood Cancer J. 2019 Jan 4;9(1):3. doi: 10.1038/s41408-018-0154-8. Blood Cancer J. 2019. PMID: 30610196 Free PMC article. Clinical Trial.

10

Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.

Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S. Nooka AK, et al. Among authors: gleason c. Cancer. 2019 Sep 1;125(17):2991-3000. doi: 10.1002/cncr.32178. Epub 2019 May 15. Cancer. 2019. PMID: 31090928 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

456 results

Search Page